# Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07912593/  
OnCo record `nct07912593` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ETX-929 run by Ensem Therapeutics, now recruiting.

## Summary

Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07912593 by Ensem Therapeutics, with 320 participants planned, started 2026-10-22. Conditions recorded: Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer, Endometrial Adenocarcinoma, Ovarian Adenocarcinoma and Primary Peritoneal Carcinoma. Interventions recorded: ETX-929 dose escalation and ETX-929 dose escalation in combination with cetuximab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07912593
- Phase: 1/2
- Setting: A Phase 1/2, First-in-Human Study of ETX-929, a Pan-KRAS Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With KRAS-Altered Advanced Solid Tumors
- Sponsor: Ensem Therapeutics
- Enrolled: 320

## Sources

- ClinicalTrials.gov NCT07912593: https://clinicaltrials.gov/study/NCT07912593

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [ETX-929](https://onco.cc/drugs/etx-929/)
- companies: [Ensem Therapeutics](https://onco.cc/companies/ensem-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07912593.json